Travere Therapeutics' EPS (Weighted Average and Diluted) rose 140.00% to $0.28 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.04, marking a year-over-year increase of 77.14%. This contributed to the annual value of -$4.08 for FY2024, which is 19.53% up from last year.
Per Travere Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at $0.28 for Q3 2025, which was up 300.00% from -$0.14 recorded in Q2 2025.
Travere Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $1.97 for Q3 2023, and its period low was -$1.76 during Q1 2024.
For the 3-year period, Travere Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.58, with its median value being -$0.71 (2024).
Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first tumbled by 4,900.00% in 2021, then spiked by 250.38% in 2023.
Travere Therapeutics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$1.46 in 2021, then increased by 8.90% to -$1.33 in 2022, then rose by 11.28% to -$1.18 in 2023, then soared by 39.83% to -$0.71 in 2024, then soared by 140.00% to $0.28 in 2025.
Its EPS (Weighted Average and Diluted) stands at $0.28 for Q3 2025, versus -$0.14 for Q2 2025 and -$0.47 for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value